中华麻醉学杂志
中華痳醉學雜誌
중화마취학잡지
Chinese Journal of Anesthesiology
2015年
7期
781-783
,共3页
翁亦齐%喻文立%杜洪印%于洪丽%贾莉莉%吕丹%王永旺%于泳浩
翁亦齊%喻文立%杜洪印%于洪麗%賈莉莉%呂丹%王永旺%于泳浩
옹역제%유문립%두홍인%우홍려%가리리%려단%왕영왕%우영호
胰蛋白酶抑制剂%肝移植%儿童%心肌%预后
胰蛋白酶抑製劑%肝移植%兒童%心肌%預後
이단백매억제제%간이식%인동%심기%예후
Trypsin inhibitors%Liver transplantation%Child%Myocardium%Prognosis
目的 探讨乌司他丁对亲体肝移植术患儿心肌损伤的影响.方法 择期全身麻醉下亲体肝移植术患儿30例,性别不限,年龄5~15个月,体重5~11 kg,ASA分级Ⅲ或Ⅳ级.采用随机数字表法,将其分为2组:对照组(C组)和乌司他丁组(U组),每组15例.U组将乌司他丁2万U/kg用生理盐水稀释至1万U/ml,分别于切皮前即刻和门静脉开放前5 min静脉注射1/2剂量;C组于相同时点给予等容量生理盐水.分别于切皮前即刻(T0)、无肝期30 min(T1)、新肝期3 h(T2)和术毕(T3)时采集中心静脉血样,检测血清心肌肌钙蛋白I(cTnI)、乳酸脱氢酶(LDH)和α-羟丁酸脱氢酶(α-HBDH)水平.记录术中多巴胺使用情况、心血管不良事件(高血压或低血压、心肌缺血和室性早搏)的发生情况.计算T1.3时血清cTnI、LDH和α-HBDH水平的变化率.结果 与C组比较,U组T2.3时血清cTnI、LDH和α-HBDH水平及其变化率降低(P<0.05或0.01),心血管不良事件发生率和多巴胺使用率差异无统计学意义(P>0.05).结论 乌司他丁可减轻亲体肝移植术患儿心肌损伤.
目的 探討烏司他丁對親體肝移植術患兒心肌損傷的影響.方法 擇期全身痳醉下親體肝移植術患兒30例,性彆不限,年齡5~15箇月,體重5~11 kg,ASA分級Ⅲ或Ⅳ級.採用隨機數字錶法,將其分為2組:對照組(C組)和烏司他丁組(U組),每組15例.U組將烏司他丁2萬U/kg用生理鹽水稀釋至1萬U/ml,分彆于切皮前即刻和門靜脈開放前5 min靜脈註射1/2劑量;C組于相同時點給予等容量生理鹽水.分彆于切皮前即刻(T0)、無肝期30 min(T1)、新肝期3 h(T2)和術畢(T3)時採集中心靜脈血樣,檢測血清心肌肌鈣蛋白I(cTnI)、乳痠脫氫酶(LDH)和α-羥丁痠脫氫酶(α-HBDH)水平.記錄術中多巴胺使用情況、心血管不良事件(高血壓或低血壓、心肌缺血和室性早搏)的髮生情況.計算T1.3時血清cTnI、LDH和α-HBDH水平的變化率.結果 與C組比較,U組T2.3時血清cTnI、LDH和α-HBDH水平及其變化率降低(P<0.05或0.01),心血管不良事件髮生率和多巴胺使用率差異無統計學意義(P>0.05).結論 烏司他丁可減輕親體肝移植術患兒心肌損傷.
목적 탐토오사타정대친체간이식술환인심기손상적영향.방법 택기전신마취하친체간이식술환인30례,성별불한,년령5~15개월,체중5~11 kg,ASA분급Ⅲ혹Ⅳ급.채용수궤수자표법,장기분위2조:대조조(C조)화오사타정조(U조),매조15례.U조장오사타정2만U/kg용생리염수희석지1만U/ml,분별우절피전즉각화문정맥개방전5 min정맥주사1/2제량;C조우상동시점급여등용량생리염수.분별우절피전즉각(T0)、무간기30 min(T1)、신간기3 h(T2)화술필(T3)시채집중심정맥혈양,검측혈청심기기개단백I(cTnI)、유산탈경매(LDH)화α-간정산탈경매(α-HBDH)수평.기록술중다파알사용정황、심혈관불량사건(고혈압혹저혈압、심기결혈화실성조박)적발생정황.계산T1.3시혈청cTnI、LDH화α-HBDH수평적변화솔.결과 여C조비교,U조T2.3시혈청cTnI、LDH화α-HBDH수평급기변화솔강저(P<0.05혹0.01),심혈관불량사건발생솔화다파알사용솔차이무통계학의의(P>0.05).결론 오사타정가감경친체간이식술환인심기손상.
Objective To investigate the effects of ulinastatin on myocardial injury in pediatric patients undergoing living-related liver transplantation (LRLT).Methods Thirty pediatric patients of both sexes, aged 5-15 months, weighing 5-11 kg, with American Society of Anesthesiologists physical status Ⅲ or Ⅳ, scheduled for elective LRLT, were equally and randomly divided into either control group (group C) or ulinastatin group (group U) using a random number table.Ulinastatin 20 000 U/kg was diluted into 10 000 U/ml with normal saline, and it was then injected intravenously in 2 parts (1/2 was injected before skin incision;1/2 at 5 min before portal vein declamping) in group U.In group C, the equal volume of normal saline was given instead of ulinastatin.Immediately before skin incision (T0, baseline), at 30 min of anhepatic phase (T1), at 3 h of neohepatic phase (T2), and at the end of surgery (T3) , blood samples were taken from the central vein for determination of serum cardiac troponin I (cTnI) , lactate dehydrogenase (LDH) , and alpha-hydroxybutyrate dehydrogenase (α-HBDH) levels.The requirement for dopamine and occurrence of adverse cardiovascular events (hypertension or hypotension, myocardial ischemia and ventricular premature beat) were recorded during surgery.The changing rates of serum cTnI, LDH and α-HBDH levels were calculated at T1-3.Results Compared with group C, the serum cTnI, LDH and α-HBDH levels and the changing rates were significantly decreased at T2-3, and no significant changes were found in the incidence of adverse cardiovascular events and requirement for dopamine in group U.Conclusion Ulinastatin can attenuate the myocardial injury in pediatric patients undergoing LRLT.